Eli Lilly’s Michael Kopach says retatrutide leads in obesity treatment and CMC innovation

Inside Tech’s Feverish Demand for Retatrutide, a Supposed Super Peptide

ClinicalTrials.gov

Triple hormone drug retatrutide shows promise for diabetes and weight loss in Lancet trial

A new triple hormone drug called retatrutide, which mimics GLP-1, GIP, and glucagon, has shown promising results in a Lancet-published trial

Spotify

A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature Metabolism

Unapproved weight-loss drug retatrutide widely available online, creating challenges for clinicians

Retatrutide, an investigational triple hormone receptor agonist not yet approved by the FDA for any indication, is being widely sold online